These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15777580)

  • 1. [Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
    Desramé J; Duvic C; Bredin C; Béchade D; Artru P; Brézault C; Defuentes G; Poirier JM; Dourthe LM; Coutant G; Chaussade S; de Gramont A; Algayres JP
    Rev Med Interne; 2005 Mar; 26(3):179-88. PubMed ID: 15777580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hemolytic uremic syndrome induced by gemcitabine. A poorly recognized complication?].
    Graas MP; Houbiers G; Demolin G; Stultiens A; Focan C
    Rev Med Liege; 2012 Dec; 67(12):644-8. PubMed ID: 23342875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.
    Saif MW; McGee PJ
    JOP; 2005 Jul; 6(4):369-74. PubMed ID: 16006690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-associated hemolytic-uremic syndrome.
    Walter RB; Joerger M; Pestalozzi BC
    Am J Kidney Dis; 2002 Oct; 40(4):E16. PubMed ID: 12324937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.
    Lee HW; Chung MJ; Kang H; Choi H; Choi YJ; Lee KJ; Lee SW; Han SH; Kim JS; Song SY
    Gut Liver; 2014 Jan; 8(1):109-12. PubMed ID: 24516709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.
    Glezerman I; Kris MG; Miller V; Seshan S; Flombaum CD
    Clin Nephrol; 2009 Feb; 71(2):130-9. PubMed ID: 19203505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma.
    Nieto-Ríos JF; Zuluaga-Quintero M; Higuita LM; Rincón CI; Galvez-Cárdenas KM; Ocampo-Kohn C; Aristizabal-Alzate A; Florez-Vargas AA; Zuluaga-Valencia GA
    J Bras Nefrol; 2016 Jun; 38(2):255-9. PubMed ID: 27438981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hemolytic-uremic syndrome associated with gemcitabine use: report of one case].
    Vega J; Parodi C; Méndez GP; Goecke H
    Rev Med Chil; 2013 Jun; 141(6):797-802. PubMed ID: 24121585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemolytic uremic syndrome following gemcitabine treatment].
    Bourquin V; Guinand A; Haenni C; Giovannini M; Delouche D; Dettwiler S; Moll S
    Rev Med Suisse; 2008 Apr; 4(154):1056-61. PubMed ID: 18557535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.
    Fung MC; Storniolo AM; Nguyen B; Arning M; Brookfield W; Vigil J
    Cancer; 1999 May; 85(9):2023-32. PubMed ID: 10223245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.
    Ritchie GE; Fernando M; Goldstein D
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):1-7. PubMed ID: 27497971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-induced hemolytic uremic syndrome in ovarian carcinoma.
    Kalra N; Kad R; Osama S
    Int J Clin Oncol; 2007 Oct; 12(5):385-7. PubMed ID: 17929123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
    Müller S; Schütt P; Bojko P; Nowrousian MR; Hense J; Seeber S; Moritz T
    Ann Hematol; 2005 Feb; 84(2):110-4. PubMed ID: 15340761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemolytic-uremic syndrome complicating a long-term treatment with gemcitabine. Report of a case and review of the literature].
    Dilhuydy MS; Delclaux C; Pariente A; De Precigout V; Aparicio M
    Rev Med Interne; 2002 Feb; 23(2):189-92. PubMed ID: 11876063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A 42-year-old patient with the hemolytic-uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine].
    Eckel F; Lersch C; Erdmann J; Schmidt B; Schulte-Frohlinde E
    Z Gastroenterol; 2000 Jul; 38(7):593-6. PubMed ID: 10965557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports
.
    López Rubio ME; Rodado Martínez R; Illescas ML; Mateo Bosch E; Martinez Díaz M; de la Vara Inesta L; Cabezuelo B; Morales Albuja ME; Lucas Guillén E; Jimeno García L
    Clin Nephrol; 2017 Feb; 87 (2017)(2):100-106. PubMed ID: 27879189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemolytic-uremic syndrome caused by gemcitabine.
    Nackaerts K; Daenen M; Vansteenkiste J; Vandevelde A; Van Bleyenbergh P; Demedts M
    Ann Oncol; 1998 Dec; 9(12):1355. PubMed ID: 9932169
    [No Abstract]   [Full Text] [Related]  

  • 18. [Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening].
    Desramé J; Duvic C; Béchade D; Bredin C; Raynaud JJ; Defuentes G; Dourthe LM; Algayres JP
    Gastroenterol Clin Biol; 2006 Feb; 30(2):332-4. PubMed ID: 16565677
    [No Abstract]   [Full Text] [Related]  

  • 19. [A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
    Wato M; Inaba T; Ishikawa H; Ishikawa S; Baba N; Miyoshi M; Senoh T; Nagano T; Takaguchi K; Watanabe S; Kawai K
    Nihon Shokakibyo Gakkai Zasshi; 2010 Oct; 107(10):1676-85. PubMed ID: 20938119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.
    Bharthuar A; Egloff L; Becker J; George M; Lohr JW; Deeb G; Iyer RV
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):177-81. PubMed ID: 19116715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.